MedTrace Logo

A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level

NCT03427710 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-09-22

No results posted yet for this study

Summary

The primary objective of the study is to assess pharmacokinetics, dynamics, safety and tolerability of CiVi007 following single and multiple subcutaneous doses in subjects, including those on statin therapy

Conditions

Interventions

DRUG

CiVi007

cholesterol lowering drug

OTHER

Placebo

matching placebo to CiVi007

Sponsors & Collaborators

  • Civi Biopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Jim Bush, MBChB, PhD · Covance

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-07
Primary Completion
2020-02-14
Completion
2020-08-18

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03427710 on ClinicalTrials.gov